Lifeboat Foundation

A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing.

Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical trials after the FDA cleared an investigational new drug application, according to the company’s press release.

EBT-101 is under development as a potential virus-clearing treatment for patients with HIV—or, put in the company’s words, “a potential functional cure for chronic HIV.”

Progress.

Replacing or editing disease-causing mutations holds great promise for treating many human diseases. Yet, delivering therapeutic genetic modifiers to specific cells in vivo has been challenging, particularly in large, anatomically distributed tissues such as skeletal muscle. Here, we establish an in vivo strategy to evolve and stringently select capsid variants of adeno-associated viruses (AAVs) that enable potent delivery to desired tissues. Using this method, we identify a class of RGD motif-containing capsids that transduces muscle with superior efficiency and selectivity after intravenous injection in mice and non-human primates. We demonstrate substantially enhanced potency and therapeutic efficacy of these engineered vectors compared to naturally occurring AAV capsids in two mouse models of genetic muscle disease. The top capsid variants from our selection approach show conserved potency for delivery across a variety of inbred mouse strains, and in cynomolgus macaques and human primary myotubes, with transduction dependent on target cell expressed integrin heterodimers.

Watch the full documentary on Vimeo on demand: https://vimeo.com/ondemand/339083

The study of consciousness needs to be lifted out of the mysticism that has dominated it. Consciousness is not just a matter of philosophy or spirituality. It’s a matter of hard science. It’s a matter of understanding the brain and the mind — a pattern structure made out of information. It’s also a matter of engineering. If we can understand the functionality of the brain, its neural code, then we can build the same functionality into our computer systems. There’s no consensus on what produces consciousness, but everyone regardless of metaphysical views can agree what it is like to be conscious. Given that consciousness is subjectivity, what consciousness is like is what consciousness is.

Continue reading “Consciousness: Evolution of the Mind, Documentary (2021), Official Teaser Trailer” »

A new electric solar car project with a living extension and expandable solar panels is giving us a glimpse into what the future might hold for RV/van life.

Solar Team Eindhoven, a group of engineering students from the Technical University of Eindhoven (Netherlands), is probably the most famous team that has competed in the World Solar Challenge, a competition to create super-efficient solar cars.

The people behind Lightyear came up from that team, and now they are trying to use the knowledge acquired through the creation of the original Stella and Stella Lux solar cars to bring to market a road-legal solar car.

A company formed by Harvard genetics professor George Church, known for his pioneering work in genome sequencing and gene splicing, hopes to genetically resurrect woolly mammoths.

Within the last decade, scientists have adapted CRISPR systems from microbes into gene editing technology, a precise and programmable system for modifying DNA. Now, scientists at MIT’s McGovern Institute and the Broad Institute of MIT and Harvard have discovered a new class of programmable DNA modifying systems called OMEGAs (Obligate Mobile Element Guided Activity), which may naturally be involved in shuffling small bits of DNA throughout bacterial genomes.

These ancient DNA-cutting enzymes are guided to their targets by small pieces of RNA. While they originated in bacteria, they have now been engineered to work in human cells, suggesting they could be useful in the development of gene editing therapies, particularly as they are small (~30% the size of Cas9), making them easier to deliver to cells than bulkier enzymes. The discovery, reported in the journal Science, provides evidence that natural RNA-guided enzymes are among the most abundant proteins on earth, pointing toward a vast new area of biology that is poised to drive the next revolution in genome editing technology.

The research was led by McGovern investigator Feng Zhang, who is James and Patricia Poitras Professor of Neuroscience at MIT, a Howard Hughes Medical Institute investigator, and a core institute member of the Broad Institute. Zhang’s team has been exploring natural diversity in search of new molecular systems that can be rationally programmed.

Check out our second promo for #transvision #future Summit 2021 (#madrid Oct. 8 — 12), featuring the optional dinner/cocktails we are scheduling, and 2 full-day #tours of several #unescoworldheritage sites and historical places near Madrid: Segovia, Ávila, Monsaterio de El Escorial & Valley of the Fallen on Oct. 11 and Alcalá de Henares, Aranjuez & Toledo on Oct. 12. It’s going to be espectacular! You don’t wanna miss those, so get your tickets now! 😊 Get your tickets here -> www.TransVisionMadrid.com.

The event itself will be a lot of fun, so make sure to register to come to Madrid in person, or to watch it via streaming (at a reduced price). There will be talks about #longevity #artificialintelligence #cryonics and much much more.

Continue reading “#TransVision Future Summit 2021 • Welcome to Madrid 8 — 12 October • Dinners & UNESCO site tours” »

Wageningen is one of a clutch of research institutions globally that hold patents on CRISPR, a technique that enables precise changes to be made to genomes, at specific locations. Other institutions — including the Broad Institute in Cambridge, Massachusetts, and the University of California, Berkeley, which have some of the largest portfolios of patents on the subject — also provide CRISPR tools and some intellectual property (IP) for free for non-profit use. But universities could do better to facilitate access to CRISPR technologies for research.

Universities hold the majority of CRISPR patents. They are in a strong position to ensure that the technology is widely shared for education and research.

An NYU-based research team created microscopic cells out of a polymer that can do active transport, a process all living cells do that is difficult to replicate.